Page last updated: 2024-09-03

imatinib mesylate and Acute Myelogenous Leukemia

imatinib mesylate has been researched along with Acute Myelogenous Leukemia in 96 studies

Research

Studies (96)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	49 (51.04)	29.6817
2010's	34 (35.42)	24.3611
2020's	13 (13.54)	2.80

Authors

Authors	Studies
Brunner, AM; Dal Cin, P; De Angelo, DJ; Dias-Santagata, D; Iafrate, AJ; Le, LP; Lennerz, JK; Luskin, MR; Marble, HD; Mueller, SB; Nardi, V; Stone, RM; Weinstock, MJ	1
Abdel Hamid, M; Aref, S; Ayed, M; El-Sokkary, AMA; Fathy El-Metwaly, N	1
Lv, K; Tong, W	1
Chiriches, C; Guillen, N; Guy, C; Heesom, KJ; Khan, D; Ottmann, OG; Rokicki, M; Ruthardt, M; Wieske, M; Wilson, M	1
Allan, JM; Blair, HJ; Dannoura, A; Dueñas, ME; Heidenreich, O; Heunis, T; Inns, J; Marín-Rubio, JL; Martin, MP; Peltier-Heap, RE; Saxty, B; Scott, J; Simpson, AJ; Trost, M; Watt, JE	1
da Costa Guimarães, RF; da Silva Santos, N; de Carvalho Pires, MG; de Oliveira Mota, F; de Sousa, AVL; de Toledo, SRC; Delbuono, E; Gamba, FT; Gouveia, JT; Oliveira, ID; Rhein, BN	1
Chada, K; D'Armiento, JM; Shiomi, T; Sonett, J; Unachukwu, U; Woode, D	1
Chen, B; Guan, J; Ma, J	1
Fei, J; Hu, H; Huang, G; Li, C; Liu, Y; Nie, H; Su, R; Wang, X; Wen, Z; Yang, J; Yin, Z; Zeng, X	1
Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W	1
Ahmadi, A; Anower-E-Khuda, F; Bajaj, J; Blevins, A; Esko, JD; Ginsberg, MH; Hamilton, M; Ito, T; Karlseder, J; Koechlein, CS; Kritzik, M; Kwon, HY; Lytle, N; Park, PW; Reya, T; Spinler, K; Sun, H; Weeks, J; Zimdahl, B	1
Adams, D; Advani, AS; Ali-Osman, F; Carew, JS; Cooper, B; Corrigan, D; Cotta, CV; Elson, P; Fensterl, J; Foster, B; Griffiths, EA; Jia, X; Kalaycio, M; Li, H; Maciejewski, JP; Park, J; Rao, AV; Rizzieri, DA; Rouphail, B; Rush, ML; Sekeres, MA; Sobecks, RM; Tripp, B; Tse, W; Wang, ES	1
Cai, Y; Du, X; Fan, JC; Liu, HX; Wang, JX; You, WW	1
Agarwal, K; Paulose, RM; Rani, PK; Tyagi, M	1
Ankathil, R; Azlan, H; Baba, AA; Dzarr, AA	1
Belyaeva, EA; Bernhardy, AJ; Bhatia, R; Bhatia, S; Bolton-Gillespie, E; Dasgupta, Y; Hanamshet, K; Johnson, N; Langer, S; Lee, J; Matlawska-Wasowska, K; Mazin, AV; Moore, M; Müschen, M; Nieborowska-Skorska, M; Siciliano, M; Skorski, T; Sullivan-Reed, K; Valent, P; Wasik, MA; Zhao, H	1
Bombelli, S; Boultwood, J; Branford, S; Citterio, S; Crespiatico, I; D'Aliberti, D; Fontana, D; Gambacorti-Passerini, C; Khandelwal, P; Kim, DW; Magistroni, V; Massimino, L; Mauri, M; Mezzatesta, C; Morotti, A; Nava, M; Parker, W; Perego, R; Piazza, R; Pirola, A; Readelli, S; Rigolio, R; Saglio, G; Schreiber, A; Sharma, N; Viltadi, M; Wang, P; Yeung, D	1
Guo, X; Zhang, X	1
Battezzi, A; Bernardinetti, M; Bove, T; Parisella, L; Tomasino, S; Vetrugno, L	1
Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM	1
Arai, H; Handa, T; Iso, H; Mitani, K; Nagasawa, F; Nakamura, Y; Sasaki, K; Takahashi, W; Tokita, K; Tsurumi, S	1
Druker, BJ	2
Doki, N; Harada, H; Harada, Y; Inoue, D; Izawa, K; Kakihana, K; Katayama, Y; Kawabata, KC; Kitamura, T; Kitaura, J; Maehara, A; Matsui, T; Nakahara, F; Nishimura, K; Ohashi, K; Oki, T; Sada, A; Togami, K; Uchida, T; Yoshioka, K	1
Garcia-Manero, G; Khoury, JD; Loghavi, S; Shah, S	1
Fujii, S; Miura, I; Tanaka, H	1
Goryainova, NV	1
Mihaila, RG	1
Ishikawa, T; Maruoka, H; Shimomura, Y	1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR	1
Becker, H; Berg, T; Binder, M; Dierks, C; Duque-Afonso, J; Hackanson, B; Lairmore, MD; Lübbert, M; Martens, U; Mertelsmann, R; Schäfer, HS; Schnitzler, M; Zeiser, R	1
Berdel, WE; Choudhary, C; Evers, G; Hehn, S; Müller-Tidow, C; Ng, PR; Sargin, B; Serve, H; Tickenbrock, L	1
Dvorak, P; Hruba, M; Subrt, I	1
Chevallier, P; Dauriac, C; Garand, R; Harousseau, JL; Hunault-Berger, M; Larosa, F	1
Cambazard, F; Chraïbi, R; Labeille, B; Perrot, JL	1
Bendit, I; de Alencar Fischer Chamone, D; de Mello Conchon, MR; Dias, L; Dorlhiac-Llacer, PE; Ferreira, P; Kumeda, C; Lima, W	1
Bacher, U; Bokemeyer, C; Bruemmendorf, TH; Dierlamm, J; Hochhaus, A; Schafhausen, P; Schnittger, S; Zander, AR	1
Beelen, DW; Ditschkowski, M; Haferlach, C; Schulte, C; Trenschel, R	1
Kondo, T; Kubo, Y; Matsuda, K; Matsuhashi, Y; Nakanishi, H; Sadahira, Y; Sano, F; Sugihara, T; Tasaka, T; Tohyama, K; Wada, H	1
Hackanson, B; Lübbert, M; Rückert, A	1
Adil, SN; Kumar, S; Masood, N	1
Ozawa, K	1
Ishizawa, J; Saya, H	1
Jotterand, M; Muehlematter, D; Rausch, T; Spertini, O; Stalder, M; Védy, D	1
Frankel, AE; Hogge, DE; Kim, HP	1
Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B	1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A	1
Chen, Y; Li, D; Li, S; Peng, C	1
Brandwein, JM; Chow, S; Gupta, V; Hedley, DW; Kamel-Reid, S; Minden, MD; Schimmer, AD; Schuh, AC; Xu, W; Yee, KW	1
Angelopoulou, MK; Bartzi, V; Bitsani, A; Boutsikas, G; Dimou, M; Efthymiou, A; Georgiou, G; Kyrtsonis, MC; Panayiotidis, P; Pessach, I; Plata, E; Tofas, P; Vardounioti, I; Vassilakopoulos, TP	1
Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM	1
Fedorova, TV; Ilinskaya, ON; Kretova, OV; Makarov, AA; Mitkevich, VA; Petrushanko, IY; Prassolov, VS; Spirin, PV; Tchurikov, NA	1
Allan, DS; Huang, H; Luo, Y; Sun, J; Tan, Y; Wang, Z	1
Eisenberg, S	1
Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C	1
Huang, LS; Tong, JF; Xu, XH; Yang, J; Yu, T; Yuan, XG; Zhao, XY	1
Kanzaki, S; Kure, A; Okuno, K; Sano, H; Tamoto, N; Ueyama, J	1
Ding, YL; Ge, CH; Li, CY; Li, W; Lian, WX; Ning, HM; Xu, CW; Xu, WX; Yang, XM; Yang, Y; Yu, M; Zhan, YQ; Zhang, MJ	1
Chan, M; Choong, A; Chu, S; Chuah, C; Goh, YT; Hwang, W; Koh, M; Lim, TJ; Linn, YC; Loh, Y; Ng, HJ; Niam, M; Suck, G; Yong, HX	1
Aritaka, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sekiguchi, Y; Sugimoto, KJ	1
Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT	1
Al-Riyami, AZ; Forrest, D; Hudoba, M; Young, S	1
Boulton, C; Fabbro, D; Gilliland, DG; Griffin, JD; Kelly, LM; Manley, P; Meyer, T; Weisberg, E	1
Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A	1
Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK	1
Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Salvado, A; Talpaz, M; Thomas, D	1
Naoe, J	1
Karp, JE; Lancet, JE	1
Feng, R; Tan Tai, LF; Yi, ZS	1
Cain, J; Grisolano, JL; O'Neal, J; Tomasson, MH	1
Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Miura, T; Obara, S; Tanaka, J; Tsutsumi, Y; Yamato, H	1
Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S	1
Chen, B; Chen, GQ; Chen, J; Chen, SJ; Chen, Z; Jin, XL; Liang, WX; Liu, YW; Shen, ZX; Shi, JY; Wang, YY; Xiong, SM; Xu, F; Yang, G; Yin, T; You, JH; Zhou, GB	1
Asou, N; Kawakita, T; Matsuno, N; Mitsuya, H; Nanri, T	1
Bergholz, U; Besmer, P; Cammenga, J; Fiedler, W; Horn, S; Sommer, G; Stocking, C	1
Chang, Y; Chen, SS; Fu, JY; Li, JL; Liu, YR; Ma, X; Qin, YZ; Ruan, GR; Wang, YZ	1
Golovleva, I; Lazarevic, V; Nygren, I; Wahlin, A	1
Kizaki, M	1
Abruzzo, LV; Cortes, J; Garcia-Manero, G; Kantarjian, H; Kovitz, C	1
Basic, I; Chandra, J; Giles, F; Golemovic, M; Kantarjian, H; Manshouri, T; Orsolic, N; Quintás-Cardama, A; Scappini, B; Verstovsek, S	1
Horiike, S; Misawa, S; Taniwaki, M; Ueda, K; Zen, K	1
Bainbridge, T; Corless, CL; Gatter, K; Granter, S; Harrell, P; Heinrich, MC; Lacouture, M; Le, C; White, C	1
Arai, Y; Eguchi, M; Eguchi-Ishimae, M; Maki, K; Mitani, K; Nakamura, Y; Sasaki, K; Tadokoro, J; Tokita, K	1
Baer, MR; Barcos, M; Coignet, LJ; Nganga, A; Pawarode, A; Sait, SN	1
Borneo, J; Chan, RJ; Kapur, R; Munugalavadla, V; Sims, EC	1
Colucci, F; Hamrouni, A; Hetuin, D; Jouy, N; Liu, J; Marchetti, P; Quesnel, B; Saudemont, A	1
Cho, BS; Eom, KS; Kim, CC; Kim, HJ; Lee, JW; Lee, S; Min, WS	1
Raaijmakers, MH	1
Alberti, D; Arpinati, M; Baccarani, M; Candoni, A; Fanin, R; Lauria, F; Malagola, M; Martinelli, G; Messa, E; Paolini, S; Piccaluga, PP; Pirrotta, MT; Rancati, F; Rondoni, M; Russo, D; Saglio, G; Vinaccia, V; Visani, G	1
Albitar, M; Bhalla, K; Cortes, J; Faraji, H; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; O'Brien, S; Ottmann, O	1
Kranz, S; Mohren, M; Neum, S; Schalk, E; Scheinpflug, K	1
Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A	1
Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S	1
Draznin, J; Parisi, E; Porter, D; Schuster, SJ; Sollecito, TP; Stoopler, E	1

Reviews

22 review(s) available for imatinib mesylate and Acute Myelogenous Leukemia

Article	Year
De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230 Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Philadelphia Chromosome	2023
[Acute myeloid leukemia with FIP1L1-PDGFRA fusion gene treated with imatinib: a case report and literature review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020, 12-14, Volume: 41, Issue:12 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myeloid, Acute; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2020
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. Pharmacogenomics, 2018, Volume: 19, Issue:5 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Pharmacogenetics; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors	2018
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:6 Topics: Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles	2015
[THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA]. Likars'ka sprava, 2014, Issue:12 Topics: Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Core Binding Factor Alpha 2 Subunit; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Proto-Oncogene Proteins c-kit; Treatment Outcome; Tretinoin; WT1 Proteins	2014
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2015, Volume: 159, Issue:4 Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation	2015
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic	2009
Old disease, new targets. Part-II, haematological malignancies. JPMA. The Journal of the Pakistan Medical Association, 2009, Volume: 59, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Costs; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Time Factors	2009
[History, current status, and future prospects in clinical study of myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Design; Drug Therapy, Combination; Gene Targeting; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Precision Medicine; Pyrimidines; Remission Induction; Risk; Tretinoin	2009
[Current clinical trials using new targeted therapies for myeloid leukemia and the research trends]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplastic Stem Cells; Piperazines; Pyrimidines; Translational Research, Biomedical; Tretinoin	2009
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Current medicinal chemistry, 2011, Volume: 18, Issue:5 Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1	2011
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature. Human pathology, 2012, Volume: 43, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic	2012
C-kit-positive acute myelogenous leukemia effectively treated with imatinib: a case report and review of the literature. Geriatrics & gerontology international, 2012, Volume: 12, Issue:4 Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2012
[True polycythemia: current views of pathogenesis, diagnostics and treatment]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:8 Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hematocrit; Hemodilution; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myeloid, Acute; Mutation; Piperazines; Platelet Aggregation Inhibitors; Polycythemia Vera; Prevalence; Primary Myelofibrosis; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Thrombosis; Treatment Outcome	2012
[Pathophysiology and treatment of acute myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; fms-Like Tyrosine Kinase 3; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Tretinoin	2003
Farnesyl transferase inhibitors in myeloid malignancies. Blood reviews, 2003, Volume: 17, Issue:3 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myeloid, Acute; Models, Biological; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinolones; ras Proteins; Signal Transduction	2003
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. American journal of hematology, 2004, Volume: 77, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2004
New therapeutic approach for myeloid leukemia: induction of apoptosis via modulation of reactive oxygen species production by natural compounds. International journal of hematology, 2006, Volume: 83, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Hemorrhage; Humans; Imatinib Mesylate; Infections; Leukemia, Myeloid, Acute; Piperazines; Pyrimidines; Reactive Oxygen Species	2006
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood, 2006, Oct-15, Volume: 108, Issue:8 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Risk Factors	2006
ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia, 2007, Volume: 21, Issue:10 Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Benzamides; Cell Differentiation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Models, Biological; Phenotype; Piperazines; Protein Binding; Pyrimidines	2007
Acute myelogenous leukemia: advances and limitations of treatment. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 93, Issue:3 Topics: Adult; Aminoglycosides; Anthracyclines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Case-Control Studies; Cytarabine; Fatal Outcome; Gemtuzumab; Gingiva; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Immunotoxins; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Piperazines; Pyrimidines; Remission Induction; Sialic Acid Binding Ig-like Lectin 3	2002

Trials

9 trial(s) available for imatinib mesylate and Acute Myelogenous Leukemia

Article	Year
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Young Adult	2021
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult	2013
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Experimental hematology, 2014, Volume: 42, Issue:5 Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Blast Crisis; Female; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; mRNA Cleavage and Polyadenylation Factors; Mutation, Missense; Neoplasms, Experimental; Oncogene Proteins, Fusion; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Transcription Factor HES-1	2014
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia research, 2008, Volume: 32, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors	2008
A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leukemia research, 2009, Volume: 33, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Rate; Time Factors	2009
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leukemia research, 2010, Volume: 34, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; STAT5 Transcription Factor	2010
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. Leukemia, 2011, Volume: 25, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Phosphorylation; Piperazines; Prognosis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Treatment Outcome	2011
A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy, 2012, Volume: 14, Issue:7 Topics: Adult; Benzamides; CD3 Complex; CD56 Antigen; Cytokine-Induced Killer Cells; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines	2012
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. Haematologica, 2007, Volume: 92, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Rate	2007

Other Studies

65 other study(ies) available for imatinib mesylate and Acute Myelogenous Leukemia

Article	Year
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood advances, 2022, 01-08, Volume: 6, Issue:3 Topics: Eosinophilia; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Receptor Protein-Tyrosine Kinases; Retrospective Studies	2022
CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome. Asian Pacific journal of cancer prevention : APJCP, 2021, Oct-01, Volume: 22, Issue:10 Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors; Treatment Outcome; Young Adult	2021
Waking up CML leukemia stem cells for the kill. Blood, 2022, 02-03, Volume: 139, Issue:5 Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Stem Cells	2022
Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia. Annals of hematology, 2022, Volume: 101, Issue:10 Topics: Chromosomal Proteins, Non-Histone; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Oncogene Proteins; Oncogene Proteins, Fusion; Poly-ADP-Ribose Binding Proteins; Signal Transduction; Translocation, Genetic	2022
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia. Journal of medicinal chemistry, 2022, 09-22, Volume: 65, Issue:18 Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proteome; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2022
NUP214::ABL1: A Ph-like fusion found in a pediatric acute myeloid leukemia patient with normal karyotype. Pediatric blood & cancer, 2023, Volume: 70, Issue:5 Topics: Child; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotype; Leukemia, Myeloid, Acute; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases	2023
Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis. Molecular cancer therapeutics, 2023, 07-05, Volume: 22, Issue:7 Topics: Angiomyolipoma; Animals; Apoptosis; Imatinib Mesylate; Kidney Neoplasms; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; TOR Serine-Threonine Kinases; Tuberous Sclerosis; Tumor Suppressor Proteins; Tyrosine Kinase Inhibitors	2023
System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 117 Topics: Animals; Berberine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Stem Cells	2023
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report. Current medical research and opinion, 2020, Volume: 36, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous	2020
A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia. Nature communications, 2020, 11-26, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Blast Crisis; Chemoradiotherapy; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Knock-In Techniques; Gene Knockout Techniques; Genes, Reporter; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Integrin beta Chains; Leukemia, Myeloid, Acute; Mice, Transgenic; Neoplastic Stem Cells; RNA-Binding Proteins; RNA-Seq; Signal Transduction; Syndecan-1	2020
Retinal haemorrhages: a clue to the underlying leukaemia. BMJ case reports, 2017, Sep-25, Volume: 2017 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorescein Angiography; Fovea Centralis; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Referral and Consultation; Retinal Hemorrhage; Tomography, Optical Coherence; Vision, Low; Visual Fields	2017
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell reports, 2018, 06-12, Volume: 23, Issue:11 Topics: Animals; BRCA1 Protein; BRCA2 Protein; DNA Repair; Female; Fusion Proteins, bcr-abl; Homologous Recombination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, Knockout; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Rad52 DNA Repair and Recombination Protein; Synthetic Lethal Mutations; Tumor Suppressor p53-Binding Protein 1	2018
Haematologica, 2019, Volume: 104, Issue:9 Topics: Blast Crisis; Cell Differentiation; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Sequence Analysis, DNA; Ubiquitin-Conjugating Enzymes	2019
Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction	2019
Cardiac tamponade and graft versus host disease: one more reason to remember. Tumori, 2018, Volume: 104, Issue:6 Topics: Biomarkers; Cardiac Tamponade; Echocardiography; Graft vs Host Disease; Heart Function Tests; Hematopoietic Stem Cell Transplantation; Hemodynamics; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardiocentesis; Treatment Outcome	2018
[Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Phenotype; Piperazines; Pyrimidines; Thiazoles	2013
Janet Rowley (1925-2013). Nature, 2014, Jan-23, Volume: 505, Issue:7484 Topics: Benzamides; Genetics, Medical; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms; Piperazines; Pyrimidines; Translocation, Genetic; United States	2014
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. Journal of hematology & oncology, 2014, Mar-27, Volume: 7 Topics: Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2014
Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia. International journal of hematology, 2017, Volume: 105, Issue:5 Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Cyclic GMP-Dependent Protein Kinase Type II; Cytogenetic Analysis; Fatal Outcome; Gene Fusion; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Signal Transduction; Translocation, Genetic; Treatment Outcome	2017
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. Cancer research, 2008, Jul-15, Volume: 68, Issue:14 Topics: Adolescent; Adult; Age Factors; Aged; Animals; Benzamides; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid, Acute; Medical Oncology; Mice; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transcription Factors	2008
Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia. International journal of hematology, 2008, Volume: 88, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; beta Catenin; Cell Line; Cell Transformation, Neoplastic; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Glycogen Synthase Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Tandem Repeat Sequences; Transfection; Wnt Proteins	2008
Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 3; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Pyrimidines	2009
[Porphyria cutanea tarda in a patient presenting hepatitis C treated with imatinib]. Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:11 Topics: Benzamides; Hepatitis C; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Porphyria Cutanea Tarda; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2008
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. International journal of hematology, 2009, Volume: 89, Issue:1 Topics: Benzamides; Chromosomes, Human, Pair 7; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult	2009
Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. Cancer genetics and cytogenetics, 2009, Volume: 189, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic	2009
Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. Bone marrow transplantation, 2009, Volume: 44, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines	2009
Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. Leukemia research, 2009, Volume: 33, Issue:9 Topics: Aged; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Mass Spectrometry; Piperazines; Polymerase Chain Reaction; Pyrimidines	2009
Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-20, Volume: 28, Issue:3 Topics: Antineoplastic Agents; Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Sarcoma, Myeloid	2010
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia research, 2010, Volume: 34, Issue:8 Topics: Adult; Aged; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Diphtheria Toxin; Drug Synergism; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles	2010
Role of Pten in leukemia stem cells. Oncotarget, 2010, Volume: 1, Issue:2 Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Thiazoles	2010
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib. Leukemia, 2012, Volume: 26, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Philadelphia Chromosome; Piperazines; Pyrimidines	2012
Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes. Cell cycle (Georgetown, Tex.), 2011, Dec-01, Volume: 10, Issue:23 Topics: Animals; Apoptosis; Bacillus; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Core Binding Factor Alpha 2 Subunit; Drug Screening Assays, Antitumor; Endoribonucleases; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Lentivirus; Leukemia, Myeloid, Acute; Mice; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; RUNX1 Translocation Partner 1 Protein; Time Factors	2011
Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Acta haematologica, 2012, Volume: 127, Issue:3 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Daunorubicin; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Homologous; Young Adult	2012
The case of the harmful herbs. ONS connect, 2012, Volume: 27, Issue:2 Topics: Benzamides; Drug Interactions; Herbal Medicine; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines	2012
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia. Gene, 2012, Jun-15, Volume: 501, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine	2012
Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome. Leukemia & lymphoma, 2013, Volume: 54, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2013
[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:4 Topics: Adolescent; Benzamides; Core Binding Factor Alpha 2 Subunit; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Mutation; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Thiazoles; Transcription Factors	2012
Erythroid differentiation-associated gene interacts with NPM1 (nucleophosmin/B23) and increases its protein stability, resisting cell apoptosis. The FEBS journal, 2012, Volume: 279, Issue:16 Topics: Apoptosis; Benzamides; Cycloheximide; Down-Regulation; Gene Knockdown Techniques; HEK293 Cells; Humans; Imatinib Mesylate; Immunoprecipitation; K562 Cells; Leukemia, Myeloid, Acute; Nuclear Proteins; Nucleophosmin; Piperazines; Pyrimidines; Tetradecanoylphorbol Acetate	2012
Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia. Leukemia & lymphoma, 2013, Volume: 54, Issue:8 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome	2013
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer cell, 2002, Volume: 1, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Protein Kinase C; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Staurosporine; Transfection; Tumor Cells, Cultured	2002
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood, 2003, Apr-15, Volume: 101, Issue:8 Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy	2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in medicine, 2003, Mar-15, Volume: 22, Issue:5 Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine	2003
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Molecular cancer therapeutics, 2003, Volume: 2, Issue:3 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured	2003
Overcoming resistance to imatinib by combining targeted agents. Molecular cancer therapeutics, 2003, Volume: 2, Issue:3 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Pyridines; Pyrimidines	2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recurrence	2003
[In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia]. Zhongguo shi yan xue ye xue za zhi, 2003, Volume: 11, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2003
An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, Aug-05, Volume: 100, Issue:16 Topics: 3T3 Cells; Acetylation; Animals; Benzamides; Blotting, Southern; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; DNA; Flow Cytometry; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mice; Mice, Inbred BALB C; Mice, Transgenic; Models, Genetic; Mutation; Oncogene Proteins, Fusion; Phenotype; Piperazines; Plasmids; Protein Binding; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Retroviridae; RUNX1 Translocation Partner 1 Protein; Time Factors; Transcription Factors; Vorinostat	2003
Monitoring of plasma imatinib concentration for the effective treatment of CML patients. Leukemia research, 2004, Volume: 28, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Body Height; Body Weight; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome	2004
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proceedings of the National Academy of Sciences of the United States of America, 2005, Jan-25, Volume: 102, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Benzamides; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic	2005
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia, 2005, Volume: 19, Issue:9 Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 16; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Remission Induction	2005
Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood, 2005, Dec-01, Volume: 106, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Core Binding Factors; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mice; Mutagenesis, Site-Directed; Mutation; Piperazines; Pyrimidines; Stem Cell Factor	2005
Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leukemia research, 2006, Volume: 30, Issue:9 Topics: Adult; Apoptosis Regulatory Proteins; Benzamides; Bone Marrow Cells; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2006
Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML. American journal of hematology, 2006, Volume: 81, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines; Remission Induction	2006
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer science, 2006, Volume: 97, Issue:9 Topics: Adamantane; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Hydroquinones; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Phosphorylation; Piperazines; Pyrimidines; Tyrosine	2006
Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia. Leukemia & lymphoma, 2006, Volume: 47, Issue:9 Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2006
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. The Journal of molecular diagnostics : JMD, 2006, Volume: 8, Issue:5 Topics: Adult; Aged; Alleles; Animals; Benzamides; Cell Line; Female; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Mastocytosis; Mice; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity	2006
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia, 2007, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Chronic Disease; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Transcription, Genetic; Translocation, Genetic	2007
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leukemia research, 2007, Volume: 31, Issue:11 Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; DNA Primers; DNA, Complementary; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Pyrimidines	2007
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood, 2007, Sep-01, Volume: 110, Issue:5 Topics: Amino Acid Substitution; Animals; Antibiotics, Antineoplastic; Benzamides; Cell Proliferation; Cell Transformation, Neoplastic; Cytokines; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mice; Mice, Knockout; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Protein Subunits; Proto-Oncogene Proteins c-kit; Pyrimidines; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Sirolimus	2007
Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer research, 2007, May-01, Volume: 67, Issue:9 Topics: Animals; Apoptosis; Benzamides; DNA Methylation; Gene Expression Regulation, Leukemic; Gene Silencing; Imatinib Mesylate; Janus Kinases; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C3H; Piperazines; Promoter Regions, Genetic; Pyrimidines; STAT Transcription Factors; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; T-Lymphocytes, Cytotoxic; Transfection	2007
Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. European journal of haematology, 2007, Volume: 79, Issue:2 Topics: Adolescent; Adult; Benzamides; Chromosomes, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leukemia research, 2008, Volume: 32, Issue:6 Topics: Antineoplastic Agents; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoassay; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity	2008
Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib. Leukemia research, 2009, Volume: 33, Issue:3 Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction	2009
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular cancer therapeutics, 2008, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib	2008
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Benzamides; Cell Division; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interleukin-3; Kinetics; Leukemia, Myeloid, Acute; Leukocyte Count; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Signal Transduction; Stem Cell Factor	2001